Member Info for bewise

I wonder why RNS are not being reported on this LSE BB? Is there a tech fault with

Up 40% $16.80 :) , a gap up for us in the morning i would imagine, investors in the States understand the profitability of 554...I cant begin to imagine the sp upon successful results in 2018!

This is flying :)

Up 32% currently :)

We have the PK results to come this quarter which could be anytime then H1 18 we have the cf results which is value adding then the mother of them all at this point,copd phase 2, 400 subjects. Interesting 16months to come sp wise and then whose knows what value adding RNS can come out of the blue in my speculative opinion :) :) :)

Guys this is very good news and bodes well going forward. I would imagine Nasdaq will react extremely well and sets us up nicely for the next sets of results this quarter and into 2018. Extremely pleased that i am investor in 554 :) Please go to the vrp website and you will find the slides for this afternoon presentation. They are an encouraging read :)

significance on all of the primary and secondary endpoints," said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. "These findings extend our previous data and show that RPL554 has the potential to further improve lung function when administered as an add-on treatment to both short-acting and long-acting bronchodilators. We continue to enroll patients in our Phase 2b study to assess nebulized RPL554 for the maintenance treatment of COPD, and the data from the current study further affirms our belief that RPL554 can become a valuable addition to drugs commonly used by patients with COPD." RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have anti-inflammatory as well as bronchodilator properties, and is currently in development for the maintenance treatment of COPD patients and for the treatment of patients with cystic fibrosis. In previous clinical trials, RPL554 has been observed to result in bronchodilatory effects when used alone or as an add-on treatment to other COPD bronchodilators. These trials have shown clinically meaningful and statistically significant improvements in lung function when RPL554 is added to two commonly used bronchodilators, as compared to the improvements in lung function when either bronchodilator is administered as a single agent. RPL554 has also shown anti-inflammatory effects in a standard challenge study with COPD-like inflammation in human subjects. In these studies, RPL554 has been well tolerated. (____________________) (4) GOLD (Global initiative for Obstructive Lung Disease) treatment guidelines - standardized treatment guidelines for COPD based on an assessment of severity of symptoms Conference Call Verona Pharma will host an investment community conference call at today 8:00 a.m. Eastern Daylight Time (1:00 p.m. British Summer Time) to discuss the positive top-line data from the Phase 2a clinical trial in COPD disclosed in this press release.

Highlights -- Primary outcome measures 1 : -- RPL554, compared to placebo, produced a statistically significant (1.5 mg, p=0.002; 6 mg, p<0.001) and a clinically meaningful (>100 ml) peak FEV1 on the third day of dosing (additional bronchodilation) when administered on top of the standard bronchodilator tiotropium (Spiriva(R)). -- Average FEV1 on the third day of dosing (0 - 12 hours) of RPL554 when added on top of tiotropium was larger than that of tiotropium alone (1.5mg, p=0.099; 6 mg, p<0.001). -- Secondary outcome measures: -- Both doses of RPL554 produced a statistically significant faster onset of action2 (1.5 mg, 4.2 min; 6 mg, 4.6 min) when added to tiotropium compared to tiotropium alone (37.6 min; p<0.001) -- The administration of RPL554 as an add-on treatment to tiotropium caused a marked reduction in Functional Residual Capacity (1.5 mg, p<0.01; 6 mg, p<0.05) and in Residual Volume (1.5 mg, p=0.07; 6 mg, p<0.01), both measures of trapped air in the lung, as compared to tiotropium alone -- Suggesting that RPL554 treatment may reduce dyspnea, a major debilitating symptom of COPD3. -- Both doses of RPL554 were well tolerated as add-on treatments to tiotropium. -- Adverse reactions were consistent with previous studies with RPL554 and tiotropium. No cardiovascular-related or gastrointestinal related adverse reactions were reported. (__________________) (1) In the study, a p-value<0.05 is regarded as statistically significant (2) Defined as FEV(1) improvement by greater than or equal to 10% (3) Dyspnea (shortness of breath) in COPD patients is often associated with hyperinflation of the lungs resulting from a higher residual volume of air Dave Singh, M.D., Professor of Clinical Pharmacology and Respiratory Medicine, Medicines Evaluation Unit, University of Manchester and Principal Investigator in this trial, commented, "Top-line results from this Phase 2a study demonstrate the very significant improvement in lung function that can be achieved in COPD patients using RPL554 in addition to tiotropium, the most widely used LAMA treatment. These encouraging results reinforce the potential for RPL554 to provide a meaningful difference in the treatment of COPD patients." "We are pleased that RPL554 demonstrated a significant and clinically meaningful improvement in lung function of COPD patients and speeds up onset of action when it is administered as an add-on treatment to one of the most widely prescribed LAMA bronchodilators in these patients. LAMAs are the mainstay of all regimens under the GOLD(4) treatment guidelines. We observed a clear dose response with the 6 mg dose, achieving statistical significance on all of the primary and secondary endpoints," said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. "These findings extend our previous data and show that RPL554 has the potential to further improve lung function when administered as an add-on treatment to both short-acting and long-acting

Verona Pharma plc Verona Pharma Announces Positive Top-Line Data From Phase 2a Clinical Trial In Copd With Rpl554 Dosed In Ad...07/09/2017 7:00amUK Regulatory (RNS & others) TIDMVRP Achieved significant and clinically meaningful additional improvement in peak lung function and faster onset-of-action when added to tiotropium Demonstrated statistical significance across all primary and secondary efficacy outcome measures, at 6 mg dose; a clear dose response compared to 1.5 mg dose Management to hold conference call and webcast today at 8 am EDT time / 1 pm BST LONDON, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today positive top-line results from its Phase 2a clinical trial, in which RPL554 was dosed in addition to tiotropium (Spiriva(R) ), one of the most commonly used drugs to treat chronic obstructive pulmonary disease (COPD). In summary, despite the limited number of patients, the data from this Phase 2a trial demonstrated significantly improved peak lung function when RPL554 was added to tiotropium in patients with moderate-to-severe COPD. This was a double blind, placebo-controlled, three way cross-over trial in 30 subjects with COPD and included two different doses of RPL554, 1.5 mg and 6 mg, or placebo, dosed twice-daily for three days, in addition to tiotropium, a long-acting anti-muscarinic (LAMA) bronchodilator, dosed once daily (ClinicalTrials.gov Identifier: NCT03028142). The primary outcome measures for the trial were peak forced expired volume in one second (FEV(1) ) on the third day of dosing and the average FEV(1) on the third day of dosing, representing measures of lung function and duration of effect. A number of secondary outcome measures were also recorded. Of note, the 6 mg dose of RPL554 achieved statistical significance, compared to placebo, on all primary and secondary outcome measures. The data confirmed dose dependency between the two RPL554 doses. Highlights -- Primary outcome measures 1 : -- RPL554, compared to placebo, produced a statistically significant (1.5 mg, p=0.002; 6 mg, p<0.001) and a clinically meaningful (>100 ml) peak FEV1 on the third day of dosing (additional bronchodilation) when administered on top of the standard bronchodilator tiotropium (Spiriva(R)). -- Average FEV1 on the third day of dosing (0 - 12 hours) of RPL554 when added on top of tiotropium was larger than that of tiotropium alone (1.5mg, p=0.099; 6 mg, p<0.001). -- Secondary outcome measures: -- Both doses of RPL554 produced a statistically significant faster onset of action2 (1.5 mg, 4.2 min; 6 mg, 4.6 min) when added to tiotropium compared to tiotropium alone (37.6 min; p<0.001) -- The administration of RPL554 as an add-on treatment to tiotropium caused a marked reduction in Functional Residual Capacity (1.5 mg, p<0.01

Thelix = pinch of salt...lol

Word of advice guys, dont listen to unknown people on a BB, go by info released on a RNS from the company before making any judgements!

01/09/2017 7:00amUK Regulatory (RNS & others) TIDMVRP LONDON, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to announce the appointment of Stifel Nicolaus Europe Limited as its Nominated Adviser and Sole Broker with immediate effect.

The drop is off no concern, the large buys are more interesting as we are now entering Q4 and the reporting of results. Imo I would imagine a lift of the sp in anticipation of results! :)

Guys, its not a share for orphans and widows so its important to dyor before investing. Its a long term investment in my view

Imo this share is a hold as we wait the many test results which are coming our way 17/18....lets see how this plays out guys, i still remain optimistic :)

Buddy i think he can lol but 10grand is still 10grand of his own money....

Good to see :)

http://www.veronapharma.com/uploads/downloads/vrp-investor-presentation-august-2017-1502711536.pdf

I'm that confident in fact i'll buy you four, lol....If 554 is futher derisked after the next lot of results 17/18 I speculate this is how things will play out as we are now on Nasdaq: JV with payment milestones to VRP, TO or go it alone.....take your pick. :)

No major pharm will take an interest till after the results of the big one to be release next year, which will significantly derisk us imo, so its a waiting game till then....Never considered a career in PR but if vrp would like to hire me i would be glad to be added to their payroll lol...